Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31653661 | 0.92 | THRB (0.39) | POLBMAPK3THRBRXFP1LMNA | |
| SCHEMBL31653824 | 0.89 | KDM4E (0.46) | POLBLMNATP53MAPTGAA | |
| SCHEMBL31653762 | 0.87 | KDM4E (0.42) | POLBTHRBRXFP1MAPT | |
| SCHEMBL31653724 | 0.86 | POLB (0.44) | POLBRXFP1LMNATP53MAPT | |
| SCHEMBL31653877 | 0.86 | RORC (0.45) | POLBTP53MAPT | |
| SCHEMBL31677653 | 0.84 | MAPK3 (0.40) | POLBMAPK3THRBRXFP1LMNA | |
| SCHEMBL31653817 | 0.84 | MAPT (0.40) | POLBRXFP1MAPTGAA | |
| SCHEMBL31653845 | 0.84 | POLB (0.51) | POLBLMNATP53MAPTGAA | |
| SCHEMBL31653872 | 0.83 | SMN1; SMN2 (0.39) | POLBLMNATP53MAPTGAA | |
| SCHEMBL31653782 | 0.83 | MAPT (0.42) | POLBLMNATP53MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215006-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF WRN | INCYTE CORPORATION (US) | 2025-07-03 | — | — | US | claimed |
| US-20250215006-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF WRN | INCYTE CORPORATION (US) | 2025-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215006-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF WRN | WRN, BLM, RECQL | POLB 74/4885MAPK3 3692/4885THRB 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.